Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Senexis Limited logo — Small-molecule therapies targeting amyloid protein toxicity

Senexis Limited

Small-molecule therapies targeting amyloid protein toxicity

Founded 2001 United Kingdom Cambridge, United Kingdom 3 employees Total: $4.30M Biotechnology, Life Sciences +1

General Information

Company Name Senexis Limited
Founded Year 2001
Location United Kingdom Cambridge, United Kingdom
Employees 3
Industries Biotechnology, Life Sciences, Pharmaceutical
Business Model B2B, B2C, Marketplace
Revenue Model Licensing, Product Sales
Social

BounceWatch is an independent company data service, not affiliated with Senexis Limited. To contact Senexis Limited, visit senexis.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Senexis Limited compare?

A PDF of Senexis Limited and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Senexis Limited soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Senexis Limited

Senexis Limited is a promising biotechnology startup, leveraging its expertise in small-molecule therapies to address amyloid protein toxicity-related diseases. Founded in 2001, the company is headquartered in the United Kingdom and operates within the Biotechnology, Life Sciences, and Pharmaceutical industries.

Senexis is committed to pioneering breakthroughs in treating ailments associated with ageing. Their current focus is on developing innovative therapies aimed at combating Alzheimer's disease, a significant area of need within the healthcare sector. This focus positions them well in the market as demand for effective treatments rises.

The startup's last known funding was an Early VC investment of £2.90M from the Wellcome Trust on 01 January 2008. This investment reflects a strong vote of confidence from a reputable institution, underscoring the potential for Senexis's pipeline to yield impactful results.

Business keywords: small-molecule drug discovery, amyloid protein toxicity, ageing-related diseases, Alzheimer's disease treatment, protein misfolding, amyloid-related toxicity, therapeutic agents, neurodegenerative diseases, R&D in CNS, protein aggregation inhibitors, inflammation inhibition, drug development, novel treatments, pathogenic process inhibition

Services & Products

selling premium domain names
leasing domains with purchase option
secure transaction facilitation
customer support for domain acquisition

Target Customers

entrepreneurs startups business owners investors digital marketers

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Early VC £2.90M 1
Wellcome Trust
Wellcome Trust
01 Jan 2008
Seed £1.40M 2
Wellcome Trust
Wellcome Trust, BTG
01 Feb 2003

Senexis Limited Alternatives & Competitors

View All Alternatives
Senexis Limited vs
Advenchen Laboratories, LLC
Advenchen Laboratories, LLC

Pioneering novel therapies with promising small molecule kinase inhibitors for a brighter future in...

Venture round
6 employees
Biotechnology, Health Care
Senexis Limited vs
ALSP, Inc.
ALSP, Inc. United States

Pioneering small molecule therapies for neurodegenerative diseases, focusing on innovative solutions...

Debt Financing
2 employees
Biotechnology, Health Care
Senexis Limited vs
Aria Pharmaceuticals
Aria Pharmaceuticals United States

Aria Pharmaceuticals is a preclinical-stage pharmaceutical company discovering and developing novel...

Series B
4 employees
AI, Big Data
View all alternatives

FAQ About Senexis Limited

Small-molecule therapies targeting amyloid protein toxicity
Senexis Limited was founded in 2001.
Senexis Limited is headquartered in Cambridge, United Kingdom.
Senexis Limited operates in Biotechnology, Life Sciences and Pharmaceutical. Its work centres on small-molecule drug discovery, amyloid protein toxicity, ageing-related diseases and Alzheimer's disease treatment. Its customers include entrepreneurs, startups and business owners.
Senexis Limited has a B2B, B2C and Marketplace business model. Its revenue comes from Licensing and Product Sales.
Senexis Limited has approximately 3 employees.
Senexis Limited has completed 2 funding rounds, raising a total of $4.30M.
Senexis Limited offers: selling premium domain names, leasing domains with purchase option, secure transaction facilitation, customer support for domain acquisition.
Top alternatives and competitors to Senexis Limited include Advenchen Laboratories, LLC, ALSP, Inc., Aria Pharmaceuticals, Orionis Biosciences, Wren Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Senexis Limited and Advenchen Laboratories, LLC are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Senexis Limited, https://bouncewatch.com/company/senexis-limited, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes